Ron Bentsur's Trading History
| NVCTNuvectis Pharma | Jul 01, 2026 | Chairman & CEO, Director, Ten Percent Owner | Informative Buy | 250.00K | $68.16M | |
| XAIRBeyond Air | Mar 21, 2023 | Director | Informative Buy | 14.90K | $324.21K | |
| STMLStemline Therapeutics | Jun 10, 2020 | ― | Uninformative Sell | ― | $0.00 | |
| KERXKeryx Biopharma | Apr 08, 2015 | ― | Informative Sell | 18.59K | $2.61M | |
| XTLBXTL Biopharmaceuticals Sponsored ADR | ― | CEO | ― | $32.36K |
You May Also Like
Ron Bentsur insider profile FAQ
What is the percentage of profitable transactions made by Ron Bentsur?
The percentage of profitable transactions made by Ron Bentsur is 59%.
What is the average return per transaction made by Ron Bentsur?
The average return per transaction made by Ron Bentsur is 14.30%.
What stocks does Ron Bentsur hold?
Ron Bentsur holds: NVCT, KERX, XAIR, STML, XTLB stocks.
What was Ron Bentsur’s latest transaction?
Ron Bentsur’s latest transaction was an Informative Buy of $250.00K.
What was Ron Bentsur's most profitable transaction?
Ron Bentsur’s most profitable transaction was an Informative Buy of NVCT stock on November 6, 2025. The return on the trade was 225.90%.
What is Ron Bentsur's role in Nuvectis Pharma?
Ron Bentsur's role in Nuvectis Pharma is Chairman & CEO, Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.